BCR and aneurysmal bone cyst: In DLBCL, ibrutinib seems to be more effective in patients with an activated B cell-like DLBCL (ABC-DLBCL) subtype rather than in patients with germinal center B cell-like DLBCL (GC-DLBCL) due to constitutively active BCR signaling in ABC-DLBCL.